Cochrane · systematic review · CD004730
Drug treatments for managing cystic fibrosis‐related diabetes
Onady, GM, Stolfi, A · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
20
current version
GRADE rated
16
No studies
4
Included studies
NR
No studies 4 · 20%Ungraded 0 · 0%Very low 4 · 20%Low 9 · 45%Moderate 2 · 10%High 1 · 5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: insulin versus placebo for CFRD
Population: adults with CFRD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HbA1c Summary of findings: insulin vs placebo | no estimate extracted | 1 study · 39 participants | Very low Downgraded: risk of bias, imprecision |
FEV1 % predicted: change from baseline Summary of findings: insulin vs placebo | MD 1.2 | 1 study · 39 participants | Low Downgraded: risk of bias, imprecision |
FVC % predicted: change from baseline Summary of findings: insulin vs placebo | MD 0.6 | 1 study · 39 participants | Low Downgraded: risk of bias, imprecision |
BMI(kg/m²): change from baseline Summary of findings: insulin vs placebo | MD 0.41 | 1 study · 39 participants | Low Downgraded: risk of bias, imprecision |
Hypoglycemia: number of episodes Summary of findings: insulin vs placebo | RR 9.23 [0.53, 159.14] | 1 study · 55 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings: repaglinide versus placebo for CFRD
Population: adults with CFRD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HbA1c Summary of findings: repaglinide vs placebo | no estimate extracted | 1 study · 38 participants | Very low Downgraded: risk of bias, imprecision |
FEV1 % predicted; change from baseline Summary of findings: repaglinide vs placebo | MD 1.7 | 1 study · 38 participants | Low Downgraded: risk of bias, imprecision |
FVC % predicted: change from baseline Summary of findings: repaglinide vs placebo | no estimate extracted | 1 study · 38 participants | Low Downgraded: risk of bias, imprecision |
BMI (kg/m²): change from baseline Summary of findings: repaglinide vs placebo | MD 0.17 | 1 study · 38 participants | Low Downgraded: risk of bias, imprecision |
Hypoglycemia: number of episodes Summary of findings: repaglinide vs placebo | RR 12.52 [0.74, 211.2] | 1 study · 51 participants | Very low Downgraded: risk of bias, imprecision |
Summary of findings: repaglinide versus insulin for CFRD
Population: children over 12 and adults with CFRD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HbA1c (%) change from baseline Summary of findings: repaglinide vs insulin | MD 0.3 | 1 study · 67 participants | High |
FEV1 % predicted change from baseline Summary of findings: repaglinide vs insulin | no estimate extracted | 2 studies · 112 participants | Moderate Downgraded: risk of bias, imprecision |
FVC % predicted change from baseline Summary of findings: repaglinide vs insulin | no estimate extracted | 2 studies · 112 participants | Moderate Downgraded: risk of bias, imprecision |
BMI (kg/m²) change from baseline Summary of findings: repaglinide vs insulin | MD 0.24 | 1 study · 45 participants | Low Downgraded: risk of bias, imprecision |
Hypoglycemia number of episodes Summary of findings: repaglinide vs insulin | RR 1.38 [0.48, 4.01] | 2 studies · 56 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings: NPH insulin versus glargine for CFRD
Population: adults with CFRD and fasting hyperglycemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HbA1c Summary of findings: NPH insulin vs glargine | no estimate extracted | NR | No studies |
FEV1 % predicted Summary of findings: NPH insulin vs glargine | no estimate extracted | NR | No studies |
FVC % predicted Summary of findings: NPH insulin vs glargine | no estimate extracted | NR | No studies |
BMI kg/m² Summary of findings: NPH insulin vs glargine | no estimate extracted | NR | No studies |
Hypoglycemia mean number of events per participant Summary of findings: NPH insulin vs glargine | no estimate extracted | 1 study · 19 participants | Very low Downgraded: risk of bias, imprecision |